Ipsen Fails Again to Get its Tumor Drug Reclassified as a Biologic

Despite another attempt by Ipsen Biopharmaceuticals to regain market exclusivity for its injectable neuroendocrine tumor drug Somatuline Depot (lanreotide), an appeals court has ruled once more in favor of the FDA.
Source: Drug Industry Daily